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INTRODUCTION
Kawasaki disease is an acute systemic vasculitis and its diag-
nosis is made on clinical features. Main complication of the
disease is coronary artery lesion that may result in myocardial
infarction or sudden death. Coronary artery aneurysms or ecta-
sia develop in approximately 15-25% of untreated children
(1). Since the intravenous immune globulin (IVIG) and aspi-
rin therapy have been introduced, its mortality rate has de-
creased to 0.1%, but cardiac sequelae continues to occur in
about 13% of Kawasaki disease patients (2). 
The etiology of Kawasaki disease is largely unknown despite
the various suggested hypotheses. Based on epidemiologic
and clinical manifestations, it is thought that Kawasaki dis-
ease is caused by some infectious agents (3-10). Hypercyto-
kinemia and hyperchemokinemia have also been observed
and are thought to cause vascular injuries by inflammatory
reaction and immunologic activation (11). Genetic factors
are also thought to have influences on the development and
progress of Kawasaki disease (12, 13). Up to present days, Ka-
wasaki disease is thought to be an infectious disease manifest-
ed by immunologic reaction in genetically susceptable person.
Angiotensin converting enzyme (ACE) breaks down the
potent vasodilator, bradykinin to its inactivate metabolite and
catalyzes angiotensin I to angiotensin II. Angiotensin II pro-
motes hyperplasia and hypertrophy of vascular smooth mus-
cle cells, induces the production of proinflammatory cytokines
and causes endothelial dysfunction by free radical generation.
By playing an important role in cardiovascular regulatory sys-
tem, ACE gene has been proposed to be associated with var-
ious cardiovascular diseases, such as ischemic heart disease,
hypertrophic cardiomyopathy, idiopathic dilated cardiomy-
opathy, and vascular hypertrophy (14). Among the different
ACE genetic loci, the insertion/deletion polymorphism coded
within intron 16 has been studied in many literature to find
the association with such diseases. 
However, there has been few studies regarding the associa-
tion between the polymorphism of ACE gene and Kawasaki
disease. The present study investigates whether the I/D poly-
morphism of ACE gene (DD, ID, II) is associated with the
prevalence and severity of Kawasaki disease among Korean
pediatric populations.
MATERIALS AND METHODS
Study subjects
Fifty five Kawasaki patients (mean age 28.2±25.2 months)
diagnosed at Ewha Womans University Mokdong Hospital
from January 2001 to June 2003, and 43 healthy children
(mean age 28.5±17.2 months) were enrolled. Kawasaki di-
sease was diagnosed by its clinical features, that is fever last-
ing for at least 5 days, accompanied by 4 of the 5 classical
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Insertion/Deletion Polymorphism of Angiotensin Converting Enzyme
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Polymorphism of angiotensin converting enzyme (ACE) gene is reported to be asso-
ciated with ischemic heart disease, hypertrophic cardiomyopathy, and idiopathic dilat-
ed cardiomyopathy. In this study, we investigated the relationship between Kawasaki
disease and insertion/deletion polymorphism of ACE gene. Fifty five Kawasaki dis-
ease patients and 43 healthy children were enrolled. ACE genotype was evaluat-
ed from each of the subjects’ DNA fragments through polymerase chain reaction
(PCR). Frequencies of ACE genotypes (DD, ID, II) were 12.7%, 60.0%, 27.3% in
Kawasaki group, and 41.9%, 30.2%, 27.9% in control group respectively, indicating
low rate of DD and high rate of ID genotype among Kawasaki patients (p<0.01).
Comparing allelic (I, D) frequencies, I allele was more prevalent in Kawasaki group
than in control group (57.3% vs. 43.0%, p<0.05). In Kawasaki group, both genotype
and allelic frequencies were not statistically different between those with coronary
dilatations and those without. ACE gene I/D polymorphism is thought to be associ-
ated with Kawasaki disease but not with the development of coronary dilatations.
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signs: 1) bilateral bulbar conjunctival injection; 2) pharynx,
injected and/or dry fissured lips, strawberry tongue; 3) changes
of the peripheral extremities in the acute phase or periungal
desquamation in the subacute phase; 4) nonvesicular rash;
5) cervical adenopathy, ≥1.5 cm. The diagnosis was made
if he/she had typical manifestations even before less than 5
febrile days of illness. All patients were treated with immu-
noglobulin (2 g/kg) on the day of diagnosis. High dose (50
mg/kg/day) aspirin was given from the day of diagnosis and
its dosage was changed to 5 mg/kg/day after 2 nonfebrile con-
secutive days.
Two dimensional echocardiography was done to evaluate
cardiac complications. Coronary arterial lesion was defined
as following: 1) inner diameter that is >3 mm in children <5
yrs old and >4 mm in children ≥5 yrs old; 2) internal diam-
eter of a segment ≥1.5 times that of an adjacent segment;
or 3) lumen with irregular surface. Among these patients, 17
showed coronary dilatations and 38 did not. 
Informed consent was obtained from his/her parents prior
to the participation in the study. The study was approved by
the hospital’s ethics commitee.
ACE genotyping
Each of the subjects’ DNA was extracted from whole blood
at the time of diagnosis using QIAamp DNA Blood Mini
Kit (Gene Company LTD., Chai Wan, Hong Kong). DNA
fragments were amplified through polymerase chain reaction
(PCR), which was carried out in a total volume of 10  L con-
taining50 ng of genomic DNA, 200 mM dNTPs, 0.3 mM/mL
of each primers (5′ -CTGGAGACCACTCCCATCCTTTCT);
(5′ -GATGTGGCCATCACATTCGTCAGAT) in PCR buffer
with 0.5 units Taq DNA polymerase (Takara, Shiga, Japan).
After the initial denaturation step (10 min at 95℃), 35 cycles
were repeated for 30 sec at 94℃, 30 sec at 52℃, 90 sec at
72℃, and 5 min at 72℃.DNA fragments were then sepa-
rated by electrophoresis on 2.5% agarose gel.
Statistical analysis
Student’s t-test was used to compare the demographic char-
acteristics between the two groups. Chi square test and Fisher
exact test were performed to compare the genotype and allelic
frequencies between the two groups. Its frequencies were com-
pared by odds ratio. pvalue less than 0.05 was considered sig-
nificant.
RESULTS
The mean age of Kawasaki group (28 boys and 27 girls)
was 28.2±25.2 months, and that of the control group (30
boys and 13 girls) was 28.5±17.2 months. Among 55 Kawa-
saki disease patients, coronary dilatation was observed in 17
patients (8 boys and 9 girls, Table 1) 
Frequencies of ACE genotypes (DD, ID, II) were 12.7%,
60.0%, 27.3% in Kawasaki group, and 41.9%, 30.2%, 27.9%
in control group respectively, indicating low rate of DD geno-
type (p<0.01, odds ratio=0.2) and high rate of ID genotype
(p<0.01, odds ratio=3.3) among Kawasaki patients (Table 2).
Comparing allelic (I, D) frequencies, I allele was more preva-
lent in Kawasaki group than in control group (57.3% vs. 43.0
%, p<0.05, odds ratio=1.78, Table 3). 
In Kawasaki group, both genotype (DD, ID, II) and allelic
frequencies were not statistically different between those with
coronary dilatations and those without (Table 4, 5).
p>0.05. Co A., coronary artery.
Normal Co A. Dilated Co A. Total
Control
Kawasaki disease
Number 38 17 55 43
Age (month) 26.8±19.6 31.8±36.3 28.2±25.2 28.5±17.2
Sex (M:F) 20:18 8:9 28:27 30:13
Table 1. Demographic characteristics of Kawasaki disease pa-
tients and control group
*p<0.01; odds ratio=0.2; 
� p<0.01; odds ratio=3.3. ACE, angiotensin con-
verting enzyme.
DD* ID
� II
Total  No. (%)
ACE genotype
Control 18 (41.9) 13 (30.2) 12 (27.9) 43 (100.0)
Kawasaki 7 (12.7) 33 (60.0) 15 (27.3) 55 (100.0)
Table 2. Prevalence of angiotensin converting enzyme genotype
in Kawasaki disease patients and control group
*p<0.05. odds ratio=1.78.
DI
Total  No. (%)
Allele
Control 49 (57.0) 37 (43.0) 86 (100.0)
Kawasaki 47 (42.7) 63 (57.3) 110 (100.0)
Table 3. Deletion/insertion allelic prevalence of angiotensin con-
verting enzyme gene in Kawasaki disease patients and control
group
*p>0.05. Co A., coronary artery; ACE, angiotensin converting enzyme.
DD ID II
Total  No. (%)
ACE genotype
Normal Co A. 5 (13.1) 24 (63.2) 9 (23.7) 38 (100.0)
Dilated Co A. 2 (11.8) 9 (52.9) 6 (35.3) 17 (100.0)
Total 7 (12.7) 33 (60.0) 15 (27.3) 55 (100.0)
Table 4. Angiotensin converting enzyme genotype of Kawasaki
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DISCUSSION
The ACE gene is localized on chromosome 17q23 and is
characterized by a major insertion/deletion polymorphism
consisting of the presence or absence of a 287-base pair Alu
repeat sequence within intron 16 (15). Angiotensin convert-
ing enzyme is an ectoenzyme found on the external surface
of the endothelial and epithelial cell membranes. It enhances
the synthesis of angiotensin-II, that promotes proliferation,
migration, and hypertrophy of vascular smooth muscle cells.
Angiotensin II also induces the production of proinflamma-
tory cytokines and matrix metalloproteinases (16, 17). More-
over, the increased free radical generation by angiotensin-II
contributes to endothelial dysfunction (18, 19).
In humans, the ACE activity is partly under genetic con-
trol. It is suggested that about half of the interindividual dif-
ference in ACE levels may be accounted for its polymorphism
(19, 20). It is reported that mean ACE levels were lowest for
II homozygotes, highest for DD homozygotes, and interme-
diate for ID heterozygotes (18, 21). Danser et al. explained
the higher ACE levels observed in subjects with D allele than
those with the II genotype by the sequence harbored in the
insert of ACE gene. This sequence was said to be very similar
to a silencer element (22). But it is not clear whether increased
levels of ACE actually affects the levels of angiotenisn II be-
cause the renin-angiotensin system is regulated by feedback
mechanism (22).
Angiotensin converting enzyme is mainly produced by vas-
cular endothelial cells (23). In Kawasaki disease, the associat-
ed endothelial cell damage subsequently lowers the ACE level.
It is reported in some literature (24, 25) that serum ACE
levels are significantly attenuated during the acute phase, and
recovered during the convalescent phase of Kawasaki disease.
Slowik et al. (26) reported that the II genotype of ACE gene
contributes to vascular dilatation at the site of aneurysm by
1) increased bradykinin activity, 2) another polymorphism
responsible for vascular dilatation that is in linkage disequi-
librium with ACE I/D polymorphism, 3) degeneration of
endothelial cells, or 4) lack of vascular remodeling. 
There is pathological difference between adult coronary
artery disease (CAD) and that caused by Kawasaki disease.
CAD caused by Kawasaki disease is characterized by vascu-
lar intimal thickening, whereas the adult CAD is characteri-
zed by atherosclerotic lesions initiated by atheroma and plaque
formation. Thus, the pathophysiologic mechanism of myocar-
dial ischemic development is also different; in adult CAD,
plaque rupture and thrombus formation plays the important
role, whereas in Kawasaki disease, coronary arterial narrow-
ing by intimal hyperplasia is responsible (24). 
In this study, the ID genotype was more prevalent (59.3 vs.
30.2%, p<0.01), and the DD genotype (12.9 vs. 41.9%, p<
0.01) was less prevalent in Kawasaki group than in control
group. And I allele was more prevalent in Kawasaki group
than in control group. However, both genotype (DD, ID, II)
and allelic frequencies were not statistically different between
Kawasaki disease patients with coronary dilatations and those
without. Therefore, ACE gene I/D polymorphism was thought
to be associated with the prevalence of Kawasaki disease but
not with the development of coronary lesions. These results
are similar to the report by Wu et al. (13) that the DD geno-
type was present in lower frequency among Kawasaki patients
and ACE polymorphism was not associated with coronary
aneurysmal formation. These results are different from the
study by Takeuchi et al. (27) that the II genotype of ACE gene
is more prevalent in Kawasaki disease and those with coro-
nary aneurysm. These inconsistent results may be accounted
for different ethnic traits of the individual population.
In conclusion, the ID genotype is present in a significantly
higher frequency and DD in lower frequency among Kawasa-
ki disease patients than in control subjects. In addition, there
are no significant association between ACE I/D polymorphism
and the coronary artery aneurysm formation in Kawasaki dis-
ease patients. Because the study groups are relatively small
size in number, it is difficult to generalize these results. In
this study, the coronary arterial dilatation was observed in 17
out of 55 Kawasaki patients. This is higher than that in pre-
viously reported literature. It can be accounted for either 1)
longer duration from the onset of illness to the infusion of
immunoglobulin, 2) other factors that may affect the devel-
opment of coronary arterial lesions in Kawasaki disease, such
as different ethinicity or 3) selection bias caused by limited
number of enrolled institution and small number of patients.
IVIG is recommended to be given within the first 10 days
of illness and, if possible, within 7 days of illness. Since the
duration of febrile days before the diagnosis and the IVIG
infusion were 4.6±1.6 days (range, 2-8 days) in our study
groups, the first explanation seems less likely. 
Further study is required to clarity the association.
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